Abstract 1325P
Background
Sunvozertinib (DZD9008) is a rationally designed, irreversible EGFR inhibitor targeting EGFR mutations with wild-type EGFR selectivity. Primary analysis of two ongoing pivotal studies (WU-KONG1 [NCT03974022] and WU-KONG6 [NCT05712902 & CTR20211009]) have demonstrated promising efficacy and safety of sunvozertinib in advanced NSCLC patients with EGFR Exon20 insertion mutations (exon20ins) in ≥ 2nd line settings. Herein, we reported preliminary results of sunvozertinib in treatment naïve EGFR exon20ins NSCLC.
Methods
NSCLC patients with EGFR exon20ins who did not receive prior systemic anti-cancer therapy were enrolled into two ongoing studies: WU-KONG1, a multinational phase I/II study; and WU-KONG15 (NCT05559645), a phase II investigator-initiated study. Sunvozertinib was administered orally at 200 mg or 300 mg QD until discontinuation criteria were met. Efficacy analysis included patients with at least one post-treatment tumor assessment according to RECIST 1.1 by independent review committee (IRC).
Results
As of February 21, 2023, a total of 28 patients were included in the efficacy analysis (200 mg, n = 19; 300 mg, n = 9). Median age was 67 years, and 75.0% (21/28) were female. Baseline ECOG PS was 0 or 1. Majority of patients (96.4%, 27/28) had metastatic diseases at study entry, with 21.4% (6/28) having > 3 metastatic sites and 32.1% (9/28) having baseline brain metastasis (BM). The most frequent mutation subtypes included 769_ASV (39.3%, 11/28), 770_SVD (10.7%, 3/28) and others. By IRC, 20 patients achieved tumor response, with a best objective response rate (ORR) of 71.4% (200 mg, 68.4%; 300 mg, 77.8%). Median duration of response has not been reached. Safety findings were consistent with results of previous sunvozertinib studies. The most common TEAEs included diarrhea, CPK increase, and skin rash. Majority of the AEs were of CTCAE grade 1 or 2, and clinically manageable.
Conclusions
In the 1st line setting, sunvozertinib as monotherapy demonstrated promising anti-tumor efficacy and acceptable safety profile in NSCLC patients with EGFR exon20ins. A phase III, multinational, randomized study (WU-KONG28, NCT05668988) is ongoing to compare sunvozertinib to chemotherapy as 1st line treatment for EGFR exon20ins NSCLC.
Clinical trial identification
NCT03974022, NCT05559645.
Editorial acknowledgement
Legal entity responsible for the study
Dizal Pharmaceutical.
Funding
Dizal Pharmaceutical.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1057P - Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors
Presenter: Jian Li
Session: Poster session 19
1058P - Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancer
Presenter: Hsiu-Tzu Wang
Session: Poster session 19
1059P - Tertiary lymphoid structures localization and maturation heterogeneities correlate with divergent clinical outcomes and immune responses of clear cell renal cell carcinoma
Presenter: Dingwei Ye
Session: Poster session 19
1061P - Association of transcriptomic mapping of tumors with high expression of Tregs to identify surfaceome gene signatures with efficacy to check point inhibitors
Presenter: María Del Mar Noblejas Lopez
Session: Poster session 19
1062P - Anti-PD1 efficacy in European patients with advanced MSI-H/MMRd non-colorectal cancers
Presenter: Christophe Tournigand
Session: Poster session 19
1063P - Differential tumor responses are a poor prognostic factor in patients receiving immune checkpoint inhibitors
Presenter: Caterina Tozzi
Session: Poster session 19
1065P - Prospective assessment of nutritional status in patients with advanced non-small cell lung cancer and renal cell carcinoma treated with immune checkpoint inhibitors
Presenter: Federica Pecci
Session: Poster session 19
1066P - Negative impact of steroids on the efficacy of immunotherapy in a multi-tumor cohort of patients: time and dose-dependent
Presenter: Víctor Albarrán
Session: Poster session 19
1067P - The interchangeability of Immune checkpoint inhibitors
Presenter: Lonneke Timmers
Session: Poster session 19